Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 78 results for "glenmark pharmaceuticals"

Glenmark Pharma's Ankleshwar plant gets 4 FDA observations
Money Control

Glenmark Pharma's Ankleshwar plant gets 4 FDA observations

Glenmark Pharmaceuticals today said it has received four observations from the US health regulator for its Ankleshwar facility after inspection in December 2016. DNA, 1 day ago

31 images for glenmark pharmaceuticals

India.com, 2 weeks ago
Forbes India, 2 weeks ago
Livemint.com, 1 month ago
Freshnews.com, 1 month ago
Hindu Business Line, 1 month ago
Pharmacy Times, 1 month ago
Pharmaceutical Tech.com, 1 month ago
Financial Express, 2 months ago
Livemint.com, 3 months ago
Freshnews.com, 3 months ago

Cipla: All-round show, prospects up

Firm's 19% y-o-y growth is way ahead of peers, Dr Reddy's and Glenmark, which delivered 2.0-6.6%
 Business Standard2 weeks ago
Rediff.com

Big pharmas' mega plan to beat competition in US

Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D. Indian pharma companies’ annual spending on research and development (R&D) might cross $2 billion by 2017-18. Companies such as Sun Pharma, Lupin and Dr Reddy’s have increased their spending to develop generic versions of complex drugs that are going off-patent in the world’s largest drug market, the US. India’s drug makers spent $1.4 ...
 Rediff.com3 days ago

Indian shares down; Tata Motors, Sun Pharma drag

* NSE index down 0.19 pct, BSE down 0.2 pct * Market to consolidate for a week - analyst By Tanvi Mehta Feb 15 (Reuters) - Indian shares fell on Wednesday, withTata Motors and Sun Pharmaceutical Industriesweighing on the indexes after posting disappointing ...
 Sify1 week ago
Forbes India

Glenmark Q3 FY17 net rises by 143%

Robust operating performance in the US business helps Glenmark post stellar earnings in an otherwise forgettable quarter for Indian pharma By Aveek Datta Forbes India Staff Published: Feb 2, 2017 Full Bio Image: Vikas Khot Mumbai-based generic drug maker ...
 Forbes India2 weeks ago Glenmark Pharma soars above 5% taking cues from its Q3 results  India Infoline2 weeks ago Glenmark Q3 net soars 143% to Rs 477 cr aided by US generic biz  Money Control2 weeks ago Glenmark Q3 net up over two-fold to Rs 477 cr  DNA2 weeks ago
DNA

Cipla, Glenmark & Sun Pharma contribute 60% to BSE Healthcare Index gains

BSE Healthcare along with BSE Telecom is trading up by over 1% on a flat day.
 India Infoline2 weeks ago Glenmark's blood pressure drug gets US FDA nod; shares up 1%  Money Control1 month ago Glenmark Pharma gets tentative US FDA nod  India Infoline1 month ago Glenmark Pharmaceuticals Q3 results on Feb 02, 2017  Money Control1 month ago
[x]  
Money Control

Glenmark Q3 profit seen up 77%, US biz may lift revenue 33%

For US business, the company may benefit from USD 2.6 billion worth Zetia generic, a cholesterol drug that launched with exclusivity on December 12 in US. Analysts expect the company to make USd 200-250 million from Zetia in 6 months.
 Money Control3 weeks ago Sanofi sues Glenmark, Torrent over sclerosis drug  Business Standard1 month ago Glenmark launches first generic version of Zetia in US  Business Standard2 months ago Glenmark launches generic version of Zetia in US  Business Standard2 months ago
[x]  

Glenmark rises 7% on strong Q3 nos; US formulation sales up 102%

The company has registered 102 percent rise in its US formulation sales at Rs 1,231 crore, while India formulation sales was up 5.9 percent at Rs 516.8 crore.
 Money Control2 weeks ago Glenmark Pharma Q3 PAT seen up 37% to Rs 310 cr: HDFC Securities  Money Control1 month ago Glenmark Q3 PAT seen up 62.6% to Rs 363.5 cr: ICICI Securities  Money Control1 month ago

Glenmark Pharma gets earnings boost

The shares of Glenmark Pharmaceuticals surged about 7 per cent in early trades on Friday on the back of strong third-quarter (Q3) earnings. The stock recorded a high of 970 and has come-off from there to current levels of 950 (up 4.6 per cent). The drug ...
 Business Line2 weeks ago Glenmark Pharma climbs nearly 7% on smart Q3 earnings  DNA2 weeks ago

Support for Nifty at 8770; buy HUL, Glenmark: Prakash Gaba

Nifty has support at 8770 and resistance at 8850 while Bank Nifty has support at 20000 and resistance at 20575, says Prakash Gaba of prakashgaba.com.
 Money Control2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less